A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects
Latest Information Update: 29 May 2025
At a glance
- Drugs HRS 9531 (Primary)
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 22 May 2025 Status changed from recruiting to completed.
- 18 Jun 2024 Status changed from not yet recruiting to recruiting.
- 03 Jun 2024 New trial record